Piper Sandler lowered the firm’s price target on Accolade to $12 from $15 ahead of the 35th Annual PSC Healthcare Conference. The firm keeps an Overweight rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACCD:
- Accolade Announces Repurchase of $76.5 Million of 0.50% Convertible Senior Notes Due 2026
- Accolade To Present at Stephens Annual Investment Conference
- Accolade pullback an overreaction to GLP-1 commentary, says Canaccord
- Accolade management to meet with William Blair
- Accolade price target lowered to $10 from $14 at Wells Fargo